Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT03593759

Cardiac Sarcoidosis Randomized Trial

Led by Ottawa Heart Institute Research Corporation · Updated on 2026-05-05

194

Participants Needed

30

Research Sites

411 weeks

Total Duration

On this page

Sponsors

O

Ottawa Heart Institute Research Corporation

Lead Sponsor

C

Canadian Institutes of Health Research (CIHR)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).

CONDITIONS

Official Title

Cardiac Sarcoidosis Randomized Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older
  • Diagnosed with cardiac sarcoidosis showing one or more of these: advanced heart block (Mobitz II or third degree), significant slow heart rate (<40 bpm awake), sustained or non-sustained ventricular arrhythmia, left ventricular ejection fraction below 50%, or right ventricular ejection fraction below 40%
  • No other explanation for these heart symptoms
  • FDG-PET nuclear imaging within 6 months showing active cardiac sarcoidosis
  • Positive biopsy for sarcoidosis (either heart or other tissue) and/or CT chest showing signs of pulmonary sarcoidosis or lymph node enlargement in chest area
Not Eligible

You will not qualify if you...

  • Current or recent (within 2 months) non-topical treatment for sarcoidosis
  • Current oral or intravenous treatment for sarcoidosis lasting more than 5 days
  • Currently taking methotrexate or prednisone for another condition
  • Intolerance or contraindication to methotrexate or prednisone
  • Does not meet all inclusion criteria
  • Unable or unwilling to provide informed consent
  • Enrolled in another randomized clinical trial
  • Contraindication to PET imaging or severe claustrophobia
  • Pregnant or breastfeeding
  • Women of childbearing age who refuse effective contraception during the study
  • Investigator believes participation is not in patient's best interest

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 30 locations

1

Yale-New Haven Hospital

New Haven, Connecticut, United States, 06520

Actively Recruiting

2

Tufts Medical Center

Boston, Massachusetts, United States, 02111

Actively Recruiting

3

University of Michigan-Michigan Medicine Cardiovascular Center

Ann Arbor, Michigan, United States, 48109-5853

Actively Recruiting

4

University of Minnesota

Minneota, Minnesota, United States, 55455

Not Yet Recruiting

5

Montefiore Medical Center

New York, New York, United States, 10467

Actively Recruiting

6

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States, 43210

Actively Recruiting

7

Allegheny General Hospital

Pittsburgh, Pennsylvania, United States, 15212

Actively Recruiting

8

University of Utah

Salt Lake City, Utah, United States, 84112

Actively Recruiting

9

Virginia Commonwealth University

Richmond, Virginia, United States, 23298-0053

Actively Recruiting

10

Libin Cardiovascular Institute of Alberta

Calgary, Alberta, Canada, T2N 2T9

Actively Recruiting

11

St. Paul's Hospital

Vancouver, British Columbia, Canada, V5Z 1M9

Actively Recruiting

12

Eastern Health Health Sciences Centre

St. John's, Newfoundland and Labrador, Canada, A1B 3V6

Actively Recruiting

13

QE II Health Sciences Centre

Halifax, Nova Scotia, Canada, B3H 3A7

Actively Recruiting

14

St. Joseph's Healthcare Centre

Hamilton, Ontario, Canada, L8N 4A6

Actively Recruiting

15

London Health Sciences Centre

London, Ontario, Canada, N6A 4A5

Actively Recruiting

16

University of Ottawa Heart Institute

Ottawa, Ontario, Canada, K1Y 4W7

Actively Recruiting

17

Montreal Heart Institute

Montreal, Quebec, Canada, H1T 1C8

Actively Recruiting

18

CIUSSS-Hopital du Sacre-Coeur de Montreal

Montreal, Quebec, Canada, H4J 1C5

Actively Recruiting

19

Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval

Québec, Quebec, Canada, G1V 4G5

Actively Recruiting

20

CIUSSS de l'Estrie - CHUS - Hôpital Fleurimont

Sherbrooke, Quebec, Canada, J1H 5N4

Actively Recruiting

21

Hokkaido University

Sapporo, Kita 8, Nishi 5, Kita-Ku, Japan, 060-0808

Actively Recruiting

22

Chiba University

Chiba, Japan

Actively Recruiting

23

University of Fukui

Fukui, Japan

Not Yet Recruiting

24

St. Marrianna University

Kawasaki, Japan

Not Yet Recruiting

25

Nagoya City University

Nagoya, Japan

Actively Recruiting

26

National Cerebral and Cardiovascular Center (NCVC)

Osaka, Japan

Actively Recruiting

27

Sapporo Medical University

Sapporo, Japan

Actively Recruiting

28

Nippon Medical School

Tokyo, Japan

Actively Recruiting

29

King's College Hospital NHS Foundation Trust

London, United Kingdom, SE5 9RS

Not Yet Recruiting

30

Imperial College Healthcare Trust-NHS-Hammersmith Hospital

London, United Kingdom, W12 0HS

Not Yet Recruiting

Loading map...

Research Team

D

David H Birnie, MD

CONTACT

J

Janine Ryan, BAH, CCRP

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here